在患者的饮食干预试验设计与一个Ileoanal Pouch:从一个随机,双盲,安慰剂控制的养研究的教训
Zaid S Ardalan1, Miles P Sparrow1, Faran Rohani1
1Department of Gastroenterology, School of Translational Medicine Monash University & Alfred Health Melbourne Australia.
概括
莫纳什囊饮食 (MPD) 恶化了症状囊患者的症状,导致早期终止试验. 这种对囊炎的饮食干预需要仔细考虑试验设计.
科学领域:
- 胃肠病学 胃肠病学
- 临床营养学 临床营养学
- 炎症性肠道疾病研究研究
背景情况:
- 皮囊炎是经过大肠囊手术后的常见并发症.
- 正在探索饮食干预措施来管理毛囊炎和相关症状.
- 提出了一种特定的整体饮食策略,即莫纳什囊饮食 (MPD).
研究的目的:
- 评估莫纳什囊饮食在治疗囊炎方面的有效性.
- 评估MPD对囊囊症状,炎症,生活质量和便特征的影响.
- 为了比较MPD与典型的澳大利亚口袋饮食.
主要方法:
- 一个随机,双盲,安慰剂控制的饮食养试验.
- 患者有症状的口袋和口袋炎的病史被纳入.
- 干预包括MPD或典型的澳大利亚饮食7周.
- 临床分数 (Pouch疾病活动指数 - PDAI),症状,耐受性,便calprotectin和生活质量都被测量.
主要成果:
- 由于MPD的所有患者的症状恶化,该试验被提前终止.
- 大多数人报告部分坚持 (50%-80%) 和不良耐受性.
- 生活质量结果各不相同,便指数没有显示出明确的饮食趋势.
结论:
- 在这项试验中,莫纳什囊饮食没有证明对囊的疗效.
- 这项研究强调,在为囊患者设计饮食试验时需要仔细考虑.
- 对有效的饮食策略进行进一步的研究是有必要的.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
450
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
450
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
637
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
637
Irritable Bowel Syndrome III: Medical and Nursing Management
641
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
641
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
826
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
826
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631


